Foamix Pharmaceuticals to Release Third Quarter 2016 Financial Results and Host Conference Call & Webcast on Wednesday, November 16

REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 7, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the third quarter ended September 30, 2016 before the market open, and will host a corporate update conference call and webcast on Wednesday, November 16, at 8:30am Eastern Time.

Conference Call & Webcast

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan.

For more information, please visit www.foamixpharma.com.

Logo - http://photos.prnewswire.com/prnh/20160906/404614LOGO

SOURCE Foamix Pharmaceuticals Ltd

Related Links

http://www.foamixpharma.com